Age-related macular degeneration causes irreversible vision loss in over twenty million patients in the US alone. Existing treatments slow progression, but have no impact on the upstream drivers of disease.

Ocutheia is pioneering a new approach to preserving vision by targeting metabolic dysfunction in photoreceptors. Our approach has broad therapeutic potential in the retina and even beyond the eye.